ArticleInternational journal of preventive medicine2026
Visualizing Emerging Trends and Global Hotspots in Ozempic, Weight Loss, and Pancreatitis Research: A Scientometric Analysis.
Article in International journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To visualize emerging trends and areas of global interest in research related to Ozempic, weight loss, and pancreatitis using scientometric tools to analyze literature published between January 2008 and January 2025. Methods: A descriptive scientometric analysis was performed by searching the Web of Science Core Collection database. The software CiteSpace and/or Bibliometrix were used to generate knowledge maps, co-citation networks, and keyword co-occurrence networks. A total of 115 documents were identified through a search that included the keywords "Ozempic," "weight loss," and "pancreatitis." The documents were filtered and selected according to predefined inclusion and exclusion criteria. Results: A stable scientific production was evidenced by the publication of a total of 115 documents in 72 journals, highlighting "Cureus Journal of Medical Science" and "Diabetes Obesity & Metabolism" as the most productive. Several different relevant thematic clusters were identified, "adverse event," and "incretins." At the level of thematic evolution, one finds that semaglutide as a term has been coming into its own in the last several years and is seen as related to obesity and type 2 diabetes. The network reflects growing interrelationships between clinical medicine, nursing, and medicinal chemistry to stimulate additional collaborative inquiry. Conclusions: This research identified the major topic areas, authors, and most relevant collaborative networks that address the patient needs and challenges presented by Ozempic, weight loss, and pancreatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.